Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus

被引：55

作者：

Briani, C

Zara, G

Rondinone, R

Della Libera, S

Ermani, M

Ruggero, S

Ghirardello, A

Zampieri, S

Doria, A

机构：

[1] Univ Padua, Dept Neurosci, Div Rheumatol, I-35128 Padua, Italy

[2] Univ Padua, Dept Med & Surg Sci, Div Rheumatol, I-35128 Padua, Italy

来源：

NEUROLOGY | 2004年 / 62卷 / 12期

关键词：

D O I：

10.1212/01.WNL.0000130499.91775.2C

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).

引用

收藏

页码：2288 / 2290

页数：3

相关论文

共 10 条

[1]

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients [J].

Bastuji-Garin, S ;

Ochonisky, S ;

Bouche, P ;

Gherardi, RK ;

Duguet, C ;

Djerradine, Z ;

Poli, F ;

Revuz, J .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (05) :1020-1026

[2]

Thalidomide-induced neuropathy [J].

Chaudhry, V ;

Cornblath, DR ;

Corse, A ;

Freimer, M ;

Simmons-O'Brien, E ;

Vogelsang, G .

NEUROLOGY, 2002, 59 (12) :1872-1875

[3]

DETECTION, CHARACTERIZATION, AND STAGING OF POLYNEUROPATHY - ASSESSED IN DIABETICS [J].

DYCK, PJ .

MUSCLE & NERVE, 1988, 11 (01) :21-32

[4]

THALIDOMIDE NEUROPATHY - A CLINICAL ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FOLLOW-UP STUDY [J].

FULLERTON, PM ;

OSULLIVA.DJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1968, 31 (06) :543-+

[5]

CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY [J].

GARDNERMEDWIN, JMM ;

SMITH, NJ ;

POWELL, RJ .

ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (12) :828-832

[6]

Thalidomide-induced neuropathy: a ganglionopathy? [J].

Giannini, F ;

Volpi, N ;

Rossi, S ;

Passero, S ;

Fimiani, M ;

Cerase, A .

NEUROLOGY, 2003, 60 (05) :877-878

[7]

p75-mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor [J].

Hamanoue, M ;

Middleton, G ;

Wyatt, S ;

Jaffray, E ;

Hay, RT ;

Davies, AM .

MOLECULAR AND CELLULAR NEUROSCIENCE, 1999, 14 (01) :28-40

[8]

HARLAND CC, 1995, EUR J CLIN PHARMACOL, V49, P1

[9]

Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus [J].

Housman, TS ;

Jorizzo, JL ;

McCarty, MA ;

Grummer, SE ;

Fleischer, AB ;

Sutej, PG .

ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :50-54

[10]

Update on therapy - thalidomide in the treatment of lupus [J].

Karim, MY ;

Ruiz-Irastorza, G ;

Khamashta, MA ;

Hughes, GRV .

LUPUS, 2001, 10 (03) :188-192